huahaipharm(SH:600521)2015-10-22 16:00Financial Performance - Operating revenue for the first nine months rose by 34.09% to CNY 2,421,920,938.11 year-on-year[7] - Net profit attributable to shareholders increased by 65.73% to CNY 335,433,909.22 for the first nine months[7] - Basic earnings per share increased by 65.38% to CNY 0.43[8] - The net profit attributable to the parent company was ¥335,433,909.22, an increase of 66% compared to ¥202,399,910.81 in the same period last year, primarily due to significant sales growth in raw materials and domestic and international formulations[15] - Net profit for the first nine months of 2015 was ¥390.25 million, up 62.0% from ¥241.05 million in the same period last year[33] - Total profit for the quarter reached ¥109.95 million, an increase of 28.8% from ¥85.42 million in Q3 of the previous year[29] - The company reported a total comprehensive income of ¥170.03 million for Q3 2015, compared to ¥120.60 million in Q3 2014, reflecting a 41.0% increase[33] Assets and Liabilities - Total assets increased by 20.59% to CNY 5,438,565,115.37 compared to the end of the previous year[7] - Non-current assets totaled ¥2,589,244,379.27, compared to ¥2,153,508,778.56, indicating an increase of about 20.2%[22] - Current liabilities rose to ¥1,747,069,429.39 from ¥1,196,996,134.29, reflecting a significant increase of approximately 46%[22] - Total liabilities reached ¥1,872,706,973.58, up from ¥1,243,941,213.38, representing an increase of around 50.5%[23] - Shareholders' equity increased to ¥3,565,858,141.79 from ¥3,266,074,939.80, showing a growth of about 9.2%[23] Cash Flow - Cash flow from operating activities decreased by 48.00% to CNY 72,384,062.27 compared to the same period last year[7] - The net cash inflow from operating activities for the first nine months of 2015 was ¥2.33 billion, compared to ¥1.77 billion in the same period last year[35] - The net cash flow from operating activities for the first nine months of 2015 was CNY 244,177,598.36, an increase of 44.0% compared to CNY 169,581,869.52 in the same period last year[38] - The net cash flow from financing activities was CNY 437,781,269.39, a significant improvement from a net outflow of CNY 485,069,479.47 in the previous year[39] - Cash inflow from sales of goods and services reached CNY 1,715,668,615.97, representing a 20.5% increase from CNY 1,423,757,869.12 in the same period last year[38] Shareholder Information - The total number of shareholders reached 19,733 by the end of the reporting period[11] - The largest shareholder, Chen Baohua, holds 26.76% of the shares, with 134,100,000 shares pledged[12] Expenses and Investments - Sales expenses increased by 60% to ¥297,853,056.87 due to heightened marketing efforts for formulation products[14] - Management expenses rose to ¥266.51 million for the first nine months of 2015, an increase of 23.6% from ¥215.57 million in the same period last year[32] - Investment cash flow showed a net outflow of ¥269,897,109.59, a 199% decrease compared to a net inflow of ¥273,652,348.39 in the previous year, attributed to acquisitions of subsidiaries[15] - The company invested CNY 268,774,691.70 in fixed assets, intangible assets, and other long-term assets, which is a slight increase from CNY 253,673,616.32 in the previous year[38] Other Financial Metrics - The weighted average return on equity improved by 3.32 percentage points to 9.98%[8] - The effective tax rate for the quarter was approximately 5.6%, compared to 12.5% in the same period last year[29] - The company reported a gross profit margin of 43.8% for Q3 2015, compared to 36.7% in Q3 2014[32] - The company has implemented its fundraising investment projects according to the planned schedule[16] - There are no significant warnings regarding potential losses or major changes in net profit compared to the same period last year[19]